Seeing Is Believing
Currently out of the existing stock ratings of Matthew Biegler, 110 are a BUY (92.44%), 9 are a HOLD (7.56%).
Analyst Matthew Biegler, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 29.7% that have a potential upside of 37.7% achieved within 102 days.
Matthew Biegler’s has documented 217 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NRIX, Nurix Therapeutics at 09-Oct-2025.
Analyst best performing recommendations are on CELU (CELULARITY).
The best stock recommendation documented was for VOR (VOR BIOPHARMA) at 3/21/2025. The price target of $8 was fulfilled within 182 days with a profit of $7.13 (819.54%) receiving and performance score of 45.03.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$2.5
$0.86 (52.44%)
$4
2 months 3 days ago
(12-Aug-2025)
2/4 (50%)
$1.37 (121.24%)
49
Buy
$2
$0.36 (21.95%)
$6
5 months 2 days ago
(13-May-2025)
6/8 (75%)
$1.04 (108.33%)
91
Hold
$4
$2.36 (143.90%)
$28
5 months 2 days ago
(13-May-2025)
1/2 (50%)
$3.04 (316.67%)
33
Hold
$3
$1.36 (82.93%)
7 months 6 days ago
(09-Mar-2025)
2/4 (50%)
$2.07 (222.58%)
111
Buy
$145
7 months 10 days ago
(05-Mar-2025)
0/1 (0%)
$52.99 (57.59%)
Which stock is Matthew Biegler is most bullish on?
Which stock is Matthew Biegler is most reserved on?
What Year was the first public recommendation made by Matthew Biegler?